Porcine epidemic diarrhea virus strain, nano antibody and antibody cocktail
Nanoantibody cocktails obtained through yeast two-hybrid technology have neutralizing activity against swine epidemic diarrhea virus (PEDV), solving the problem of poor prevention of existing vaccines and providing treatment and prevention of swine epidemic diarrhea virus New direction.
Patent Information
- Application Number
- CN202411293186.4
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-09-14
- Publication Date
- 2024-11-26
- Estimated Expiration
- 2044-09-14
AI Technical Summary
The prevention effect of existing swine epidemic diarrhea virus (PEDV) vaccines is not ideal, especially the seasonal outbreaks in newborn piglets, and there is a lack of commercial antibody therapeutics for pig diseases.
Nanoantibodies specifically targeting the PEDV-JSXH-2021 strain were screened through yeast two-hybrid technology, and nanoantibodies cocktails with neutralization were developed to prevent and treat PEDV infection.
It provides nano-antibody with non-toxic and specific binding ability in vitro, which can effectively neutralize PEDV infection, provides a new direction for the treatment and prevention of swine epidemic diarrhea virus, and has the potential to develop into an antibody therapeutic agent.
Smart Images

Figure CN119020304A_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the field of biology and new medical technology, and in particular to porcine epidemic diarrhea virus strains, nanobodies and antibody cocktails. Background Art
[0002] Porcine epidemic diarrhea (PED) is an intestinal infectious disease of pigs caused by porcine epidemic diarrhea virus (PEDV), characterized by acute diarrhea. The disease is characterized by acute watery diarrhea, vomiting, and dehydration, with a high mortality rate, especially for newborn piglets and weaned piglets. The disease was first reported in fattening pigs with diarrhea in the UK in 1971. In 1978, scientists Debouck et al. from Ghent University in Belgium successfully isolated the pathogen from the diseased pigs and named it CV777 strain. A series of experiments showed that the pathogen is pathogenic to both suckling piglets and fattening pigs. In 2010, a new highly virulent variant of PEDV (identified as G2 type) appeared in China. This new PEDV variant causes high morbidity and mortality in newborn piglets. According to reports, the G1 mutant and the G2 strain, which is distantly related to CV777, are currently in epidemic status. Vaccination is the main way to prevent PED and alleviate the epidemic. The emergence of new vaccines such as subunit vaccines, viral vector vaccines, and bacterial vector vaccines has provided more possibilities for the prevention and treatment of PED. However, it cannot be ignored that the prevention effect of existing commercial vaccines has not been ideal due to the high variability of the virus. So far, there is no effective preventive measure to respond to and control the seasonal outbreak of PED in newborn piglets. PED still causes significant economic losses to the pig industry.
[0003] A deep understanding of the structure and function of antigen epitopes is extremely critical for the development of immunotherapy drugs. As a key factor in the humoral immune system, antibodies have been used in clinical treatment as early as the late 19th century. Since then, with the continuous deepening of people's research on antibody genes and the development of molecular biology technology, the research and development of antibodies has ushered in rapid development. So far, the development of therapeutic antibodies in the field of human medicine is relatively mature, especially in tumor treatment and other aspects. At the same time, it also focuses on the development of therapeutic antibodies for serious infectious diseases. However, related research in the veterinary field is in its infancy. As one of the world's most important agricultural industries, the research on the detection and therapeutic antibodies of pig diseases has also made initial progress. Among them, nano antibodies have attracted people's attention due to their small size, easy genetic manipulation, strong specificity, and good solubility. At present, there are few reports on nano antibodies for pig diseases, and the acquisition and application of commercial antibody therapeutics are a long way to go. With the increase in market demand, it is urgent to develop antibody therapeutics for pig diseases to improve vaccine prevention and control, and to prevent and control viral infections during the vaccine window period and emergency treatment of early viral infections. Nano antibodies have become a very promising antibody research direction with their unique advantages.
[0004] Therefore, it is an urgent problem to be solved by the present invention to provide a nano antibody that can specifically bind to PEDV, is non-toxic in vitro, can effectively neutralize PEDV infection, and provides a new direction for the treatment of PEDV and the prevention of PEDV-induced diarrhea. Summary of the invention
[0005] In view of the above-mentioned prior art, the purpose of the present invention is to provide a porcine epidemic diarrhea virus strain, a nanobody and an antibody cocktail to address the problems in the prior art such as the lack of effective vaccines for PEDV. The nanobody has the characteristics of small size, easy genetic manipulation, strong specificity, good solubility, etc., which provides a new direction for the research of VHH-based drugs for the prevention and treatment of PEDV infection.
[0006] In order to achieve the above-mentioned purpose, the present invention provides a porcine epidemic diarrhea virus strain, which is the porcine epidemic diarrhea virus PEDV-JSXH-2021 strain, and its preservation number is CGMCC No.46088. It was deposited in the General Microbiology Center of China National Microbiological Culture Collection Committee on August 14, 2024, and the address of the preservation unit is No. 3, Yard 1, Beichen West Road, Chaoyang District, Beijing.
[0007] The present invention also provides a nano antibody against porcine epidemic diarrhea virus, which is obtained by yeast two-hybrid screening of the porcine epidemic diarrhea virus PEDV-JSXH-2021 strain.
[0008] Preferably, the Nanobody is a first Nanobody having an amino acid sequence as shown in SEQ ID No: 1 (its CDR1 sequence is shown in SEQ ID No: 15, its CDR2 sequence is shown in SEQ ID No: 16, and its CDR3 sequence is shown in SEQ ID No: 17); or,
[0009] The Nanobody is a second Nanobody having an amino acid sequence as shown in SEQ ID No: 2 (its CDR1 sequence is shown in SEQ ID No: 18, its CDR2 sequence is shown in SEQ ID No: 19, and its CDR3 sequence is shown in SEQ ID No: 20); or,
[0010] The Nanobody is a third Nanobody having an amino acid sequence as shown in SEQ ID No: 3 (its CDR1 sequence is shown in SEQ ID No: 21, its CDR2 sequence is shown in SEQ ID No: 22, and its CDR3 sequence is shown in SEQ ID No: 23); or,
[0011] The Nanobody is a fourth Nanobody having an amino acid sequence as shown in SEQ ID No: 4 (its CDR1 sequence is shown in SEQ ID No: 18, its CDR2 sequence is shown in SEQ ID No: 19, and its CDR3 sequence is shown in SEQ ID No: 24); or,
[0012] The Nanobody is the fifth Nanobody having an amino acid sequence as shown in SEQ ID No: 5 (its CDR1 sequence is shown in SEQ ID No: 18, its CDR2 sequence is shown in SEQ ID No: 19, and its CDR3 sequence is shown in SEQ ID No: 25); or,
[0013] The Nanobody is the sixth Nanobody having an amino acid sequence as shown in SEQ ID No: 6 (its CDR1 sequence is shown in SEQ ID No: 26, its CDR2 sequence is shown in SEQ ID No: 27, and its CDR3 sequence is shown in SEQ ID No: 28); or,
[0014] The Nanobody is the seventh Nanobody having an amino acid sequence as shown in SEQ ID No: 7 (its CDR1 sequence is shown in SEQ ID No: 18, its CDR2 sequence is shown in SEQ ID No: 19, and its CDR3 sequence is shown in SEQ ID No: 29); or,
[0015] The nanobody is the eighth nanobody with an amino acid sequence as shown in SEQ ID No: 8 (its CDR1 sequence is shown in SEQ ID No: 18, its CDR2 sequence is shown in SEQ ID No: 19, and its CDR3 sequence is shown in SEQ ID No: 30).
[0016] Preferably, the method for preparing the Nanobody specifically comprises:
[0017] S100, extracting RNA from the porcine epidemic diarrhea virus PEDV-JSXH-2021 strain and then reverse transcribing it, using the cDNA obtained after reverse transcription as a template, amplifying the porcine epidemic diarrhea virus PEDV-JSXH-2021 strain and then sequencing it to obtain the S gene sequence of the porcine epidemic diarrhea virus PEDV-JSXH-2021 strain, and connecting the S gene sequence to a vector to obtain a bait plasmid;
[0018] S200, transforming the library plasmid and the bait plasmid obtained in step S100 into yeast cells, spreading the transformed yeast cells on SD-TLH medium for culture, picking out grown single clones, and screening to obtain positive yeast clones;
[0019] S300, extracting the positive yeast clone plasmid obtained in step S300, amplifying and sequencing it by PCR, and then comparing it by Seqman and BLAST to obtain the coding gene of the nanobody;
[0020] S400, expressing the coding gene of the nanobody in step S300, and obtaining the nanobody accordingly.
[0021] Preferably, in step S100, the amplification process is segmented PCR amplification, and the S gene sequence of the porcine epidemic diarrhea virus PEDV-JSXH-2021 strain is obtained by sequencing and splicing the multiple amplification products after the segmented amplification respectively.
[0022] Preferably, the segmented PCR amplification process uses two pairs of primers for amplification, and the first amplification primer pair is shown as SEQ ID No:9 and SEQ ID No:10, and the second amplification primer pair is shown as SEQ ID No:11 and SEQ ID No:12.
[0023] Specifically, the S gene of the porcine epidemic diarrhea virus PEDV-JSXH-2021 strain is amplified in two parts (the two parts are marked as S1 gene and S2 gene respectively), and the S1 gene is amplified by the first amplification primer pair and the S2 gene is amplified by the second amplification primer pair. After amplification, the two parts of the amplified products are sequenced and spliced to obtain the complete S gene sequence. Among them, there is a partial overlap between the S1 gene and the S2 gene.
[0024] Preferably, in step S300, the PCR amplification process uses the primer pair shown in SEQ ID No: 13 and SEQ ID No: 14 for amplification; and / or,
[0025] The connection vector in step S100 is a pGBKT7 vector; and / or,
[0026] The library plasmid in step S200 is a pGADT7-VHH plasmid library.
[0027] The present invention also provides an antibody cocktail for porcine epidemic diarrhea virus, comprising at least two of the first nanobody, second nanobody, third nanobody, fourth nanobody, fifth nanobody, sixth nanobody, seventh nanobody and eighth nanobody as described above.
[0028] Preferably, the antibody cocktail comprises at least two of the first nanobody, the third nanobody, the fourth nanobody, the fifth nanobody, the sixth nanobody, the seventh nanobody and the eighth nanobody.
[0029] Preferably, the antibody cocktail comprises a first nanobody, a third nanobody, a fourth nanobody, a fifth nanobody, a sixth nanobody, a seventh nanobody and an eighth nanobody; and,
[0030] The concentration of each Nanobody in the antibody cocktail was 25-50 ng / μL.
[0031] Through the above technical scheme, the present invention discloses a porcine epidemic diarrhea virus strain, and on this basis, a specific nano antibody targeting PEDV is screened by yeast two-hybrid technology. At the same time, the obtained nano antibody has neutralizing activity against PEDV and can effectively exert an anti-PEDV effect. In addition, these nano antibodies are non-toxic in vitro and can neutralize PEDV infection by binding to different epitopes of the spike protein. The nano antibodies obtained based on the present invention have considerable potential for further development into antibody therapeutics, and also provide a theoretical basis and new research direction for the development of VHH-based drugs to treat and prevent PEDV-induced diarrhea. BRIEF DESCRIPTION OF THE DRAWINGS
[0032] The accompanying drawings are used to provide a further understanding of the present invention and constitute a part of the specification. Together with the following specific embodiments, they are used to explain the present invention but do not constitute a limitation of the present invention. In the accompanying drawings:
[0033] Figure 1A This is a diagram showing the transformation of the bait plasmid pGBKT7-PEDV-S into the recipient bacteria AH109 and the self-activation detection results thereof in Example 2;
[0034] Figure 1B It is the positive yeast clone obtained by screening in the SD-TLHA+X-α-gal screening plate in Example 2;
[0035] Figure 1C This is a diagram showing the results of the yeast positive clone rotation verification in Example 2;
[0036] Figure 2A is a graph showing the results of indirect immunofluorescence detection of the expression of PEDV S-VHHs in HEK293T cells in Example 3;
[0037] Figure 2B This is a graph showing the expression of PEDV S-VHHs in HEK293T cells detected by Western blotting in Example 3;
[0038] Figure 2C is a diagram showing the results of SDS-PAGE analysis of the protein purified in Example 4;
[0039] Figure 3A This is a result diagram of the indirect immunofluorescence detection of the specific binding of PEDV S-VHHs to S protein in Verification Example 1;
[0040] Figure 3B This is a result diagram of Western blotting detection of the specific binding of PEDV S-VHHs to S protein in Verification Example 1;
[0041] Figure 4 It is a result diagram of the indirect immunofluorescence detection of the specific binding of purified PEDV S-VHHs to PEDV in Verification Example 1;
[0042] Figure 5 It is a graph showing the results of the neutralization activity test of PEDV S-VHHs against PEDV in the application example. DETAILED DESCRIPTION
[0043] The specific embodiments of the present invention are described in detail below. It should be understood that the specific embodiments described herein are only used to illustrate and explain the present invention, and are not used to limit the present invention.
[0044] Specifically, the present invention provides a porcine epidemic diarrhea virus strain, which is the porcine epidemic diarrhea virus PEDV-JSXH-2021 strain, whose preservation number is CGMCC No.46088, and it was deposited in the General Microbiology Center of China National Culture Collection Administration on August 14, 2024.
[0045] The present invention prepares nanobodies based on the porcine epidemic diarrhea virus strain, and its preparation method is described in detail below in conjunction with specific examples.
[0046] The HiScript IV 1st Strand cDNA Synthesis Kit and 2×Phanta Flash MasterMix used are conventional commercial products of Nanjing Novozymes Biotech Co., Ltd., EZNAGel Extraction Kit is a conventional commercial product of Omega Bio-Tek, USA, T vector is a conventional commercial product of Beijing Solebow Technology Co., Ltd., library plasmid pGADT7-VHH, Yeast Colony Rapid Detection Kit, and AH109 yeast are conventional commercial products of Nanjing Ruiyuan Biotechnology Co., Ltd., X-tremeGENE HP DNA Transfection Reagent is a conventional commercial product of Roche, Switzerland, Lipo293 transfection reagent and desalting column are conventional commercial products of Beyotime Biotechnology, and HisSep Ni-NTAMagBeads are conventional commercial products of Yishen Biotechnology.
[0047] Example 1, acquisition of PEDV S gene sequence:
[0048] The RNA of porcine epidemic diarrhea virus PEDV-JSXH-2021 strain was extracted using FastPure Viral DNA / RNAMini Kit and HiScript IV 1st Strand cDNASynthesis Kit (Vazyme, Nanjing, China), and its cDNA was obtained by reverse transcription. The PEDV S gene sequence was amplified using 2×Phanta Flash Master Mix (Vazyme, Nanjing, China) with cDNA as a template. The amplification of the PEDV S gene sequence was divided into two parts, S1 gene and S2 gene. The amplification primers of S1 gene were S1-2F (SEQ ID No: 9: 5'-TGAAGAATGGTAAGTTGCTAGTGC-3') and S1-7R (SEQ ID No: 10: 5'-TGGGTGAGTAATTGTTTACAACG-3'). The primers for amplification of the S2 gene were L-PEDV-S2-F1 (SEQ ID No: 11: 5'-GGGAGTTGCCTGGTTTCTTC-3') and L-PEDV-S2-R3 (SEQ ID No: 12: 5'-CATTCACTGCACGTGGACC-3'). The amplified products of the S1 gene and the S2 gene were recovered by EZNA Gel Extraction Kit (Omega Bio-tek, Norcross, GA, USA), connected to the T vector (SolarbioScience Technology, Beijing, China) and sequenced. The S gene sequence was obtained by sequencing (i.e., the amplified S1 gene and S2 gene were sequenced and spliced), and the recombinant plasmid obtained by connecting the S gene sequence to the pGBKT7 vector was the bait plasmid, which was recorded as pGBKT7-PEDV-S.
[0049] Example 2, Screening of PEDV S-VHHs:
[0050] The PEDV-S gene connected to the pGBKT7 vector (i.e., the bait plasmid pGBKT7-PEDV-S prepared in Example 1) was used as bait to screen the pGADT7-VHH library by yeast two-hybridization. The operation steps are as follows:
[0051] First, pGBKT7-PEDV-S and pGBKT7 were transformed into AH109 for self-activation detection. The transformation method was as follows: a single colony of AH109 was picked from a YPDA plate and inoculated into 4 mL of YPDA liquid culture medium, 30°C, 225 rpm, and shaken for 18-20 hours (overnight) until OD600>1.5. Transfer to YPDA liquid culture medium, the culture volume is 50 mL, the initial OD600 is 0.2, 30°C, 225 rpm, shaken for 4-5 hours, until OD600=0.6. Centrifuge to collect bacteria, room temperature, 4000 rpm, 5 minutes. Resuspend the bacteria with 20 mL of sterile water, mix well, centrifuge to collect bacteria, room temperature, 4000 rpm, 5 minutes, and discard the supernatant. Resuspend the bacteria with 5 mL of 0.1 mol / L LiAc, mix well, centrifuge to collect bacteria, room temperature, 4000 rpm, 5 minutes, and discard the supernatant. Resuspend the bacteria with 500μL of 0.1mol / L LiAc, mix well, and dispense into 1.5mL centrifuge tubes, 50μL each (for each transformation) for later use. Add 240μL of 50% PEG3350, 36μL of 1mol / L LiAc, and 5μL of ssDNA (20mg / ml, ssDNA is pGBKT7-PEDV-S or pGBKT7 plasmid) to each 1.5mL centrifuge tube. After adding, blow and mix with a gun tip, or shake vigorously for about 1min until completely mixed. Then incubate in a 30℃ water bath for 30min, heat shock in a 42℃ water bath for 25min. Resuscitate in a 30℃ water bath for 30min. Centrifuge to collect bacteria, room temperature, 4000rpm, 5min, discard the supernatant. For each transformation, 200 μL of sterile water was used to suspend the bacteria, and the mixture was mixed as gently as possible. The bacteria were spread on SD-T (SD / -Trp) plates and cultured at 30°C for 3-4 days to obtain yeast cells transformed with the bait plasmid pGBKT7-PEDV-S (i.e., the AH109 yeast strain containing the bait plasmid pGBKT7-PEDV-S). Three cloning points were randomly selected and placed on SD-T, SD-TH (SD / -Trp / -His), SD-THA (SD / -Trp / -His / -Ade), and SD-THA+X-α-gal plates and cultured at 30°C for 3-5 days. pGBKT7 was used as a negative control. The results of the transformation of the bait plasmid pGBKT7-PEDV-S into the recipient bacteria AH109 and its self-activation detection are shown in the figure. Figure 1A As shown. Figure 1A It can be seen that the negative control pGBKT7 can grow on SD-T plates, but cannot grow normally on SD-TH, SD-THA, and SD-THA+X-α-gal plates. The growth of the experimental group is consistent with that of the control group. This indicates that the bait plasmid pGBKT7-PEDV-S has no self-activation phenomenon.
[0052] Library screening: Use the AH109 yeast strain containing the bait plasmid pGBKT7-PEDV-S obtained above as the receptor to prepare the competent state, transfer the library plasmid pGADT7-VHH (Ruiyuan biotechnology, Nanjing, China) into it, and apply SD-TLH (SD / -Trp / -Leu / -His) screening plates, a total of 20 plates. Culture at 30°C for 3-7 days, and observe the growth of colonies. Pick out the grown clone colonies, transfer them to SD-TLHA (SD / -Trp / -Leu / -His / -Ade) + X-α-gal screening plates and continue to culture for 3-5 days, and screen to obtain positive yeast clones. After screening, a total of 288 positive yeast clones were obtained. The positive yeast clones obtained by screening in the SD-TLHA + X-α-gal screening plates are as follows. Figure 1B As shown, Figure 1B The + in the figure is the positive control pGADT7-largeT+pGBKT7-p53 commonly used in yeast two-hybrid assay.
[0053] Yeast positive clone identification and sequencing comparison: The 288 positive yeast clones obtained above were amplified using the Yeast Colony Rapid Detection Kit (Ruiyuan biotechnology, Nanjing, China). The amplification primer pair used for positive yeast cloning was T7-F: TAATACGACTCACTATAGG (SEQ ID No: 13), BD-R: GAATTAGCTTGGCTGCAAGC (SEQ ID No: 14). After DNA sequencing and BLAST comparison analysis, 8 different gene sequences were finally obtained (as shown in Table 2). The 8 obtained gene sequences were expressed correspondingly, and the 8 corresponding amino acid sequences obtained were shown in Table 1 (wherein "*" in Table 1 corresponds to the terminator in the gene sequence in Table 2), and the 8 different amino acid sequences obtained were uniformly recorded as VHH antibody sequences.
[0054] The yeast positive clones containing the 8 different gene sequences obtained above were rotated and verified: the positive clones streaked on the SD-TLHA+X-α-gal defective plate were diluted with sterile water and spotted on SD-TL, SD-TLH, SD-TLHA, and SD-TLHA+X-α-gal defective plates, and cultured at 30°C for 3-4 days. The yeast positive clone rotation verification results are as follows: Figure 1C As shown. Among them, Figure 1CThe + in the figure is the positive control pGADT7-largeT+pGBKT7-p53, which is commonly used in yeast two-hybrid assays. The - in the figure is the negative control pGADT7-largeT+pGBKT7-laminC, which is commonly used in yeast two-hybrid assays. Figure 1C It can be seen that the positive control can grow on SD-TL, SD-TLH, SD-TLHA, SD-TLHA+X-α-gal defective plates, and can show blue on SD-TLHA+X-α-gal defective plates; the negative control can only grow on SD-TL plates, but not on other plates. The 8 yeast positive clones screened can grow normally on SD-TL, SD-TLH, SD-TLHA defective plates, and can show blue on SD-TLHA+X-α-gal plates. Therefore, it is confirmed that the present invention obtains 8 PEDVS-VHHs interacting with the bait plasmid pGBKT7-PEDV-S through yeast two-hybrid screening, and the obtained PEDV S-VHHs express nanobodies correspondingly, and the expressed nanobodies (i.e., PEDV S-VHH expression proteins) are named VHH1-4 (i.e., the first nanobody), VHH1-15 (i.e., the second nanobody), VHH1-41 (i.e., the third nanobody), VHH1-89 (i.e., the fourth nanobody), VHH2-18 (i.e., the fifth nanobody), VHH2-28 (i.e., the sixth nanobody), VHH2-50 (i.e., the seventh nanobody), and VHH2-77 (i.e., the eighth nanobody). The amino acid sequences of the eight nanobodies are shown in Table 1.
[0055] Table 1
[0056]
[0057]
[0058]
[0059] Table 2
[0060]
[0061]
[0062]
[0063]
[0064] Example 3, eukaryotic expression of PEDV S-VHHs:
[0065] The eight PEDV S-VHHs obtained above were expressed in the cell lines HEK293 T and FreeStyle 293-F, respectively (based on the need to perform multiple simultaneous tests on the eight PEDV S-VHHs in subsequent experiments, therefore, when the eight PEDV S-VHHs need to be tested in parallel using the same operation method, they are all simplified as PEDV S-VHHs). When the confluence of HEK293 T cells reaches 70%-90%, the plasmid DNA (pcDNA3.1-VHH) is transferred into the cells using X-tremeGENE HP DNA Transfection Reagent (Roche, Basel, Switzerland). After 72 hours, the culture supernatant and cell pellet were collected to detect the expression of PEDV S-VHHs expression proteins.
[0066] When the cell density of Freestyle 293-F cells in 50 mL suspension culture reaches about 2×10 6 / mL, and transfection is performed when the cell survival rate is >90%. Take two clean sterile centrifuge tubes and add 1.25mL of Freestyle 293-F cell culture medium without antibiotics and serum to each tube; then add 50μg of plasmid DNA (pCDNA3.1-VHH) to one tube and 100μL of Lipo293 transfection reagent (Beyotime Biotechnology, Shanghai, China) to the other tube, and mix them gently with a pipette. Then add the culture medium containing DNA to the culture medium containing Lipo293 transfection reagent with a gun, gently invert the centrifuge tube or mix it gently with a gun, and let it stand at room temperature for 15 minutes. Add all 2.5mL of Lipo293 transfection reagent-DNA mixture to 50mL of suspended Freestyle 293-F cells. After continuing to culture in a shaking incubator at 37℃, 125rpm, 8% CO2 for 72h, collect the cells for expression detection of the target protein. Figure 2A To detect the expression of PEDV S-VHHs in HEK293T cells by indirect immunofluorescence, mouse anti-his tag monoclonalantibody was used to label VHH1-4, VHH1-15, VHH1-41, VHH1-89, VHH2-18, VHH2-28, VHH2-50, and VHH2-77, respectively. Bar = 100 μm; Figure 2BTo detect the expression of PEDV S-VHHs in HEK293T cells by Western blotting, mouse anti-his tag monoclonal antibody was used to label VHH1-4, VHH1-15, VHH1-41, VHH1-89, VHH2-18, VHH2-28, VHH2-50, and VHH2-77, respectively. The target protein size was approximately 15 kDa. Figure 2A and Figure 2B It can be seen that (the control group is a FreeStyle293-F cell precipitate sample transferred with an empty vector.), IFA and Western blotting assays both indicate that PEDV S-VHHs are successfully expressed. Compared with VHH1-4, VHH1-15, VHH1-41, VHH2-18, and VHH2-28, the expression levels of VHH1-89, VHH2-50, and VHH2-77 are lower.
[0067] Example 4: Protein purification and renaturation:
[0068] VHHs expressed in FreeStyle 293-F cells were purified using HisSep Ni-NTAMagBeads (Yeasen Biotechnology, Shanghai, China). Collect 50 mL of FreeStyle 293-F cells 72 hours after transfection, add Lysis Buffer according to the ratio of cells: Lysis Buffer = 1:10 (W / V), add PMSF with a final concentration of 1 mmol / L, and disrupt the cells by ultrasound on ice until the disrupted liquid remains basically clear. Add Lysis Buffer (containing 8 mol / L urea) to the disrupted liquid to a total volume of 40 mL. Mix overnight at 4°C to completely dissolve the inclusion body protein. Centrifuge at 15,000×g, 4°C for 15 min, transfer the supernatant to a new 50 mL centrifuge tube, add magnetic beads to it, and mix by inversion overnight at 4°C. After washing with Wash Buffer (containing 8 M urea) 5 times, add Elution Buffer (containing 8 mol / L urea) to elute the protein. The eluted protein was renatured by desalting column (Beyotime Biotechnology, Shanghai, China). The concentration of PEDV S-VHHs obtained by final renaturation was uniformly adjusted to 200 ng / μL for subsequent experiments. It was placed at -80°C for use. The purified protein was analyzed by SDS-PAGE (the control group was a FreeStyle 293-F cell pellet sample transferred with an empty vector). Figure 2CAs shown, VHH1-4, VHH1-15, VHH1-41, VHH1-89, VHH2-18, VHH2-28, VHH2-50, and VHH2-77 have a single and obvious protein band near the 15kDa position, and the protein size is in line with expectations, indicating that the above 8 PEDV S-VHHs were successfully purified. After the above purified antibodies were treated with a desalting column for renaturation, their concentrations were measured as follows: 0.914μg / μL, 0.271μg / μL, 0.593μg / μL, 0.359μg / μL, 0.228μg / μL, 0.596μg / μL, 0.322μg / μL, and 0.386μg / μL.
[0069] Verification Example 1: Whether PEDV S-VHHs can bind to PEDV and S protein:
[0070] The binding activity of PEDV S-VHHs to PEDV S protein was evaluated by IFA and Western blotting. In the present invention, the PEDV S protein used to detect the reactivity of PEDV S-VHHs was obtained by expressing the S protein in Sf9 cells using the PEDV S protein recombinant baculovirus expression plasmid pFastBac1-PEDV-S. By IFA detection, Figure 3A As shown in Figure 2, the renatured VHH1-4, VHH1-15, VHH1-41, VHH1-89, VHH2-18, VHH2-28, VHH2-50, and VHH2-77 were all able to detect the PEDV S protein expressed in Sf9 cells. In addition, the S protein-expressing Sf9 cell samples were collected, and the supernatant was taken for Western blotting experiments after ultrasonic disruption. The results were as expected, and the PEDV S-VHHs were able to specifically detect a band of about 180 KDa, indicating that they all bound to the PEDV S protein (as shown in Figure 2). Figure 3B As shown). In order to further confirm whether the purified PEDV S-VHHs specifically bind to PEDV, IFA analysis was performed. The results showed that VHH1-4, VHH1-15, VHH1-41, VHH1-89, VHH2-18, VHH2-28, VHH2-50, and VHH2-77 were able to stain Vero cells infected with the PEDV-JSXH-2021 strain, but did not react with uninfected control cells, indicating that the purified PEDV S-VHHs specifically bind to PEDV (as shown). Figure 4 shown).
[0071] Verification Example 2: Neutralization of PEDV by PEDV S-VHHs:
[0072] In order to determine the neutralizing activity of these eight VHHs against PEDV, a neutralization experiment was performed. The concentration of the PEDVS-VHHs obtained by final refolding was uniformly adjusted to 200 ng / μL, and serial dilutions were used for neutralization detection. Figure 5 As shown in AG, VHH1-4, VHH1-41, VHH1-89, VHH2-18, VHH2-28, VHH2-50, and VHH2-77 have neutralizing titers against PEDV-JSXH-2021 strains, and their highest coefficients are 1:2, 1:8, 1:16, 1:4, 1:4, 1:8, and 1:16, respectively, and the corresponding virus neutralization titers are 100ng / μL, 25ng / μL, 12.5ng / μL, 50ng / μL, 50ng / μL, 25ng / μL, and 12.5ng / μL, respectively. No neutralizing activity was observed for VHH1-15. These results indicate that VHH1-4, VHH1-41, VHH1-89, VHH2-18, VHH2-28, VHH2-50, and VHH2-77 have the potential to neutralize viral infection in vitro.
[0073] Application Examples
[0074] The seven VHHs detected to have neutralizing activity (i.e., VHH1-4, VHH1-41, VHH1-89, VHH2-18, VHH2-28, VHH2-50, and VHH2-77) were prepared into a "cocktail" antibody (each antibody was about 30 ng / μL). The results showed that the combination of these nanobodies neutralized viral infection at 6.25 ng / μL, showing a better effect than using nanobodies alone. The specific results are as follows Figure 5 shown. Figure 5 In the figure, the graphs marked with AG correspond to the neutralization activity of VHH1-4 (A), VHH1-41 (B), VHH1-89 (C), VHH2-18 (D), VHH2-28 (E), VHH2-50 (F), and VHH2-77 (G) against PEDV-JSXH-2021 strain. The initial concentration of each antibody was uniformly adjusted to 200 ng / μL. Figure 5 In the figure marked with H, the neutralizing activity test of VHH1-4, VHH1-41, VHH1-89, VHH2-18, VHH2-28, VHH2-50, and VHH2-77 against the PEDV-JSXH-2021 strain after mixing.
[0075] The present invention uses the PEDV-S gene constructed on the pGBKT7 vector as bait to screen the yeast two-hybrid nanoantibody library, and through multiple reporter gene detection, DNA sequencing and BLAST comparison analysis of positive clones, the PEDV S-VHHs that interact with pGBKT7-PEDV-S are determined. The binding specificity of these nanoantibodies to the S protein and PEDV is verified by indirect immunofluorescence staining (IFA) and Western blotting experiments, and their neutralization efficiency is verified by neutralization experiments. This lays the foundation for the development of VHH-based drugs for the prevention and treatment of PEDV infection.
[0076] The preferred embodiments of the present invention are described in detail above. However, the present invention is not limited to the specific details in the above embodiments. Within the technical concept of the present invention, a variety of simple modifications can be made to the technical solution of the present invention, and these simple modifications all belong to the protection scope of the present invention.
[0077] It should also be noted that the various specific technical features described in the above specific embodiments can be combined in any suitable manner without contradiction. In order to avoid unnecessary repetition, the present invention will not further describe various possible combinations.
[0078] In addition, various embodiments of the present invention may be arbitrarily combined, and as long as they do not violate the concept of the present invention, they should also be regarded as the contents disclosed by the present invention.
Claims
1. A porcine epidemic diarrhea virus strain, characterized in that: The porcine epidemic diarrhea virus strain is the porcine epidemic diarrhea virus PEDV-JSXH-2021 strain, whose preservation number is CGMCC No.46088, and it was deposited in the General Microbiology Center of China National Culture Collection Administration on August 14, 2024.
2. A nanobody against porcine epidemic diarrhea virus, characterized in that: The nanobody is obtained by yeast two-hybrid screening of the porcine epidemic diarrhea virus PEDV-JSXH-2021 strain.
3. The Nanobody according to claim 2, characterized in that The nanobody is a first nanobody with an amino acid sequence as shown in SEQ ID No: 1; or, The nanobody is a second nanobody with an amino acid sequence as shown in SEQ ID No: 2; or, The nanobody is a third nanobody with an amino acid sequence as shown in SEQ ID No: 3; or, The nanobody is a fourth nanobody with an amino acid sequence as shown in SEQ ID No: 4; or, The nanobody is the fifth nanobody with an amino acid sequence as shown in SEQ ID No: 5; or The nanobody is the sixth nanobody with an amino acid sequence as shown in SEQ ID No: 6; or, The nanobody is the seventh nanobody with an amino acid sequence as shown in SEQ ID No: 7; or, The nanobody is the eighth nanobody whose amino acid sequence is shown in SEQ ID No:
8.
4. The Nanobody according to claim 2 or 3, characterized in that The method for preparing the nanobody specifically comprises: S100, extracting RNA from the porcine epidemic diarrhea virus PEDV-JSXH-2021 strain and then reverse transcribing it, using the cDNA obtained after reverse transcription as a template, amplifying the porcine epidemic diarrhea virus PEDV-JSXH-2021 strain and then sequencing it to obtain the S gene sequence of the porcine epidemic diarrhea virus PEDV-JSXH-2021 strain, and connecting the S gene sequence to a vector to obtain a bait plasmid; S200, transforming the library plasmid and the bait plasmid obtained in step S100 into yeast cells, spreading the transformed yeast cells on SD-TLH medium for culture, picking out grown clone colonies, and screening to obtain positive yeast clones; S300, extracting the positive yeast clone plasmid obtained in step S300, amplifying and sequencing it by PCR, and then comparing it by Seqman and BLAST to obtain the coding gene of the nanobody; S400, expressing the coding gene of the nanobody in step S300, and obtaining the nanobody accordingly.
5. The Nanobody according to claim 4, characterized in that In step S100, the amplification process is segmented PCR amplification, and the S gene sequence of the porcine epidemic diarrhea virus PEDV-JSXH-2021 strain is obtained by sequencing and splicing the multiple amplification products after the segmented amplification.
6. The Nanobody according to claim 5, characterized in that The segmented PCR amplification process uses two pairs of primers for amplification, and the first amplification primer pair is shown as SEQ ID No:9 and SEQ ID No:10, and the second amplification primer pair is shown as SEQ ID No:11 and SEQ ID No:
12.
7. The Nanobody according to claim 4, characterized in that In step S300, the PCR amplification process uses the primer pair shown in SEQ ID No: 13 and SEQ ID No: 14 for amplification; and / or; The connection vector in step S100 is a pGBKT7 vector; and / or, The library plasmid in step S200 is a pGADT7-VHH plasmid library.
8. An antibody cocktail for porcine epidemic diarrhea virus, characterized in that: The antibody cocktail comprises at least two of the first nanobody, the second nanobody, the third nanobody, the fourth nanobody, the fifth nanobody, the sixth nanobody, the seventh nanobody and the eighth nanobody as described in claim 3.
9. The antibody cocktail according to claim 8, characterized in that The antibody cocktail comprises at least two of the first nanobody, the third nanobody, the fourth nanobody, the fifth nanobody, the sixth nanobody, the seventh nanobody and the eighth nanobody.
10. The antibody cocktail according to claim 9, characterized in that The antibody cocktail comprises a first nanobody, a third nanobody, a fourth nanobody, a fifth nanobody, a sixth nanobody, a seventh nanobody and an eighth nanobody; and, The concentration of each Nanobody in the antibody cocktail was 25-50 ng / μL.
Citation Information
Patent Citations
Porcine epidemic diarrhea virus variant obtained through separation and application thereof
CN116286679A
Nanometer antibody B3 targeting porcine epidemic diarrhea virus and application thereof
CN118005781A
Nano antibody for resisting porcine epidemic diarrhea virus S1 protein
CN118126167A
Humanized rabies virus nano-antibody, recombinant nano-antibody protein and application of humanized rabies virus nano-antibody and recombinant nano-antibody protein in preparation of rabies prevention and treatment products
CN118440190A
Cited By
Nano antibody Nb116 for resisting salmonella enteritidis as well as application and preparation method of nano antibody Nb116
CN121824746A
